Product Description: Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM)[1]. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator[2].
Applications: Neuroscience-Neurodegeneration
Formula: C21H27NO2.1/2C4H6O6
Citations: Antimicrob Agents Chemother. 2024 Oct 3:e0103524./Chemosphere. 2019 Aug;229:618-630. /Eur J Pharmacol. 2023 Nov 6:176174./Eur J Pharmacol. 2024 Jul 25:176860./Exp Brain Res. 2023 Oct 16./Pharmaceuticals (Basel). 2024 Sep 19;17(9):1234./Chemosphere. 2019 Aug;229:618-630. /Heliyon. 2023 May 29, e16631./Life Sci. 2022 Feb 17;295:120419./Neurosci Bull. 2020 Feb;36(2):153-164.
References: [1]Williams K, et al. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol. 1993 Oct;44(4):851-9./[2]Kobayashi T, et al. Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil. Neuropsychopharmacology. 2006 Mar;31(3):516-24.
CAS Number: 23210-58-4
Molecular Weight: 400.49
Compound Purity: 99.95
Research Area: Neurological Disease
Solubility: DMSO : ≥ 500 mg/mL/H2O : 5 mg/mL (ultrasonic)
Target: iGluR;Potassium Channel
Deutsch
English
